the patient. In October 1982, synthetic human insulin became the first drug created from recombinant DNA technology to be approved by the FDA. The device is kept in proximity to the sensor to allow for transfer of data; however, it can be a few feet away and still receive transmitted information. Glucose sensors have improved dramatically in the last few years and are an option for patients to gain further insight into their patterns of glucose response to tailor a more individual treatment regimen.
Therefore, diabetes treatment is aimed at keeping blood glucose levels as close to the normal range as safely possible. Some can provide a warning beep if the drop in blood sugar is occurring too quickly. Various formulations of insulin differ in the pharmacokinetics,.e., the amount of time until they begin to work and the duration of their action after injection. Insulin in pill form is ineffective since digestive enzymes in the gut break it down. The aim of diabetes treatment is to keep, within reason, blood glucose levels as near to normal as possible. The pump continuously delivers insulin, 24 hours a day.